Evolving First Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma

This opening discussion examines how first line treatment strategies for metastatic pancreatic ductal adenocarcinoma have evolved and how Nalirifox is being positioned relative to FOLFIRINOX in current clinical practice. Faculty describe how historical standards were largely driven by efficacy data, whereas contemporary decision making increasingly integrates patient specific factors alongside survival outcomes.

Panelists outline how triplet regimens have reshaped expectations in metastatic disease, prompting earlier and more nuanced treatment planning. Factors such as performance status, disease burden, comorbidities, baseline laboratory values, and patient goals are discussed as critical elements in selecting between Nalirifox and FOLFIRINOX at diagnosis.

The discussion also addresses how emerging data from ongoing triplet regimen trials are influencing clinician confidence and expanding therapeutic options. Faculty emphasize that treatment choice is no longer a binary decision but rather a tailored strategy that balances efficacy, tolerability, and the feasibility of maintaining therapy over time.

This segment establishes a framework for patient centered first line care in metastatic pancreatic ductal adenocarcinoma, highlighting the importance of aligning clinical evidence with individualized assessment to optimize outcomes.